INKT - MiNK Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

INKT

MINK THERAPEUTICS, INC.

NASDAQ

$10.72

▼ DOWN 2.55% (-0.28)

KEY STATISTICS

Market Cap$55.27 M

52w High$16.93

52w Low$8.48

Dividend Yield—

Frequency—

P/E-4.54

Volume16.98K

Shares Out.4.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jennifer S. Buell

COMPENSATION 2026

Salary$448,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$5,686

Total$2,087,881

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 15, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$35.00

Target Low$35.00

Target Median$35.00

Target Consensus$35.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$1.60M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-01-28	Reverse	1:10

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

2.94%

HOLDERS

TOP 8 OF 24 · RANKED BY POSITION SIZE

Blackrock Inc.

87.2K sh

$82.77K

Geode Capital Management, LLC

Steward Partners Investment Advisory, LLC

First Command Financial Services, Inc.

1.0K sh

$2.17K

PRICE

$10.72 ▼ DOWN 2.55% (−$0.28)

OVERLAYS

About MiNK Therapeutics, Inc.

https://minktherapeutics.com ↗

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf iNKT cell therapies, including AGENT-797 for myeloma, and is a subsidiary of Agenus Inc., based in New York.

INDUSTRY

Biotechnology

A PRODUCT MINK THERAPEUTICS, INC. IS KNOWN FOR

AGENT-797

AGENT-797 is MiNK Therapeutics' off-the-shelf allogeneic iNKT cell therapy in clinical trials for cancers and immune diseases.

COMPETITORS

COMPETITOR

MiNK Therapeutics in 2025

SENTIMENT: + POSITIVE

INNOVATION · JULY 2025

MiNK Therapeutics Stock Skyrockets Over 200% After Announcing Groundbreaking Cancer Treatment Results and Complete Remission Case

In July 2025, MiNK Therapeutics announced groundbreaking results from its cancer treatment trials for its experimental therapy, agenT-797. The announcement highlighted a complete remission in a patient with treatment-refractory metastatic testicular cancer, with the case study published in the peer-reviewed journal Nature's Oncogene. This news validated the company's core iNKT cell therapy platform and generated significant investor and media attention.

PRODUCT STRATEGY · Q3 2025 · IN PROGRESS

MiNK Therapeutics Accelerates iNKT Platform Towards Pivotal Development Following Groundbreaking Cancer Trial Results

In 2025, MiNK Therapeutics made a significant strategic push to accelerate and expand the clinical development of its allogeneic invariant natural killer T (iNKT) cell therapy platform. This strategic focus was validated by groundbreaking results from its lead candidate, agenT-797, which demonstrated durable complete remissions in late-stage, treatment-refractory cancer patients, leading to a more than 700% increase in the company's equity price at one point.

Latest News

GLOBENEWSWIRE · OCT 2, 2026

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.

READ ARTICLE